Company Overview - Zhejiang Dayang Biological Technology Group Co., Ltd. is located in Hangzhou, Zhejiang Province, and was established on January 1, 1976. The company was listed on October 26, 2020. Its main business involves the production and sales of chemical raw materials, including inorganic salts and veterinary raw materials [2]. Financial Performance - As of June 30, the company reported a revenue of 499 million yuan for the first half of 2025, representing a year-on-year growth of 14.20%. The net profit attributable to the parent company was 50.51 million yuan, showing a significant increase of 60.66% year-on-year [2]. - The company has distributed a total of 168 million yuan in dividends since its A-share listing, with 97.57 million yuan distributed over the past three years [3]. Stock Performance - Year-to-date, the stock price of Dayang Biological has increased by 79.60%. However, it has experienced a decline of 4.05% over the last five trading days and 5.43% over the last 20 days. In contrast, the stock has risen by 29.06% over the past 60 days [2]. - As of September 22, the stock price was 32.91 yuan per share, with a market capitalization of 2.764 billion yuan. The trading volume was 45.52 million yuan, with a turnover rate of 1.97% [1]. Shareholder Information - As of June 30, the number of shareholders increased to 14,200, reflecting a growth of 58.33%. The average number of circulating shares per shareholder decreased by 35.82% to 4,954 shares [2]. Business Segmentation - The company's main business revenue composition includes: 69.91% from inorganic salt products, 18.35% from veterinary raw materials, 7.46% from fluorine chemical products, and 4.28% from other products [2]. - Dayang Biological is classified under the Shenwan industry as basic chemicals - chemical raw materials - inorganic salts, and is associated with concepts such as fertilizers, biopesticides, fluorine chemicals, share buybacks, and synthetic biology [2].

Company Overview - Zhejiang Dayang Biological Technology Group Co., Ltd. is located in Dayang Town, Jiande City, Hangzhou, Zhejiang Province, and was established on January 1, 1976. The company was listed on October 26, 2020. Its main business involves the production and sales of chemical raw materials, including inorganic salts and veterinary raw materials [1][2]. Financial Performance - As of June 30, the number of shareholders for Dayang Biological increased by 58.33% to 14,200, while the average circulating shares per person decreased by 35.82% to 4,954 shares [2]. - For the first half of 2025, Dayang Biological achieved operating revenue of 499 million yuan, representing a year-on-year growth of 14.20%. The net profit attributable to the parent company was 50.51 million yuan, reflecting a year-on-year increase of 60.66% [2]. Stock Performance - On September 18, Dayang Biological's stock price fell by 2.00% to 34.28 yuan per share, with a trading volume of 21.62 million yuan and a turnover rate of 0.90%. The total market capitalization is 2.88 billion yuan [1]. - Year-to-date, Dayang Biological's stock price has increased by 87.08%. Over the past five trading days, the stock has decreased by 2.39%, while it has increased by 0.62% over the past 20 days and by 36.68% over the past 60 days [1]. Business Segmentation - The main revenue composition of Dayang Biological includes: inorganic salt products (69.91%), veterinary raw materials (18.35%), fluorine chemical products (7.46%), and other products (4.28%) [1]. - The company belongs to the Shenwan industry category of basic chemicals, specifically chemical raw materials and inorganic salts. It is associated with several concept sectors, including fertilizers, fluorine chemicals, biopesticides, share buybacks, and stock transfers [1]. Dividend Distribution - Since its A-share listing, Dayang Biological has distributed a total of 168 million yuan in dividends. Over the past three years, the cumulative dividend payout has been 97.57 million yuan [3].

Group 1 - The company, Dayang Bio, announced that neither it nor its subsidiaries have experienced overdue guarantees or been involved in lawsuits related to guarantees, nor have they incurred losses due to being ruled against in such cases [2]

证券代码：003017 证券简称：大洋生物 公告编号：2025-091 浙江大洋生物科技集团股份有限公司 关于公司对子公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、浙江大洋生物科技集团股份有限公司（以下简称"公司"）及子公司累 计担保总余额为 33,650.00 万元（包含本次担保金额），占公司最近一期（2024 年 12 月 31 日）经审计净资产的比例为 31.95%。本次担保事项在公司 2025 年度 担保额度预计范围内。 2、公司及子公司未对合并报表范围外的公司提供担保。 3、公司及子公司未发生逾期担保、涉及诉讼的担保及因担保被判决败诉而 应承担损失的情况。 公司于 2025 年 8 月 22 日召开的第六届董事会第五次会议及 2025 年 9 月 12 日召开的 2025 年第二次临时股东大会，审议通过了《关于对公司及子公司增加 担保预计额度的议案》。同意对公司及子公司向银行等金融机构提供的担保额度 增加不超过人民币 30,000.00 万元，担保范围包括但不限于申请综合授信、借款、 保函、承兑汇票、固定资产贷款 ...

Group 1 - The company is planning to construct an 800-ton hydrochloric acid aminophenol production facility, which will lead to the shutdown of the existing 600-ton production line [2] - After the completion of the new facility, the total production capacity will not be 1400 tons, as the existing line will cease operations [2]

Company Overview - Zhejiang Dayang Biological Technology Group Co., Ltd. is located in Jiande City, Hangzhou, Zhejiang Province, and was established on January 1, 1976. The company was listed on October 26, 2020. [2] - The main business involves the production and sales of chemical raw materials, including inorganic salts and veterinary raw materials. The revenue composition is as follows: inorganic salt products 69.91%, veterinary raw materials 18.35%, fluorine chemical products 7.46%, and other products 4.28%. [2] Stock Performance - As of September 16, the stock price of Dayang Biological fell by 2.10% to 33.58 CNY per share, with a trading volume of 42.01 million CNY and a turnover rate of 1.78%. The total market capitalization is 2.821 billion CNY. [1] - Year-to-date, the stock price has increased by 83.26%, but it has decreased by 7.11% in the last five trading days. Over the last 20 days, the stock price has risen by 0.33%, and over the last 60 days, it has increased by 31.22%. [2] Financial Performance - For the first half of 2025, Dayang Biological achieved operating revenue of 499 million CNY, representing a year-on-year growth of 14.20%. The net profit attributable to the parent company was 50.51 million CNY, with a year-on-year increase of 60.66%. [2] - The company has distributed a total of 168 million CNY in dividends since its A-share listing, with cumulative distributions of 97.57 million CNY over the past three years. [3] Shareholder Information - As of June 30, the number of shareholders reached 14,200, an increase of 58.33% compared to the previous period. The average number of circulating shares per person is 4,954, which is a decrease of 35.82% from the previous period. [2] Industry Classification - Dayang Biological is classified under the Shenwan industry category of basic chemicals, specifically in chemical raw materials and inorganic salts. The company is associated with several concept sectors, including fertilizers, fluorine chemicals, biological pesticides, and share buybacks. [2]

Market Overview - On September 15, the chemical raw materials sector declined by 0.16% compared to the previous trading day, with Zhenhua Co., Ltd. leading the decline [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Stock Performance - Notable gainers in the chemical raw materials sector included: - Longbai Group (002601) with a closing price of 19.62, up 5.09% and a trading volume of 667,300 shares, totaling 1.314 billion yuan [1] - ST Yatai (000691) with a closing price of 7.81, up 4.97% and a trading volume of 101,400 shares, totaling 79.1972 million yuan [1] - Jinhai Titanium Industry (000545) with a closing price of 3.69, up 4.53% and a trading volume of 1,184,600 shares, totaling 435 million yuan [1] - Major decliners included: - Zhenhua Co., Ltd. (603067) with a closing price of 17.90, down 4.33% and a trading volume of 180,800 shares, totaling 329 million yuan [2] - Sanyou Chemical (600409) with a closing price of 5.78, down 3.02% and a trading volume of 368,900 shares, totaling 216 million yuan [2] - Jinniu Chemical (600722) with a closing price of 7.09, down 2.88% and a trading volume of 319,900 shares, totaling 228 million yuan [2] Capital Flow - The chemical raw materials sector experienced a net outflow of 398 million yuan from institutional investors, while retail investors saw a net inflow of 239 million yuan [2][3] - Notable capital flows included: - Huayi Group (600623) with a net inflow of 26.8479 million yuan from institutional investors [3] - Tianyuan Co., Ltd. (002386) with a net inflow of 25.0141 million yuan from institutional investors [3] - Xue Tian Salt Industry (600929) with a net inflow of 21.3913 million yuan from institutional investors [3]

Group 1 - The core point of the news is the performance and financial details of Zhejiang Dayang Biological Technology Group Co., Ltd, which saw a stock price increase of 5.02% to 35.15 CNY per share, with a total market capitalization of 2.953 billion CNY [1] - The company was established on January 1, 1976, and went public on October 26, 2020, focusing on the production and sales of chemical raw materials, including inorganic salts and veterinary raw materials [1] - The revenue composition of the company is as follows: 69.91% from inorganic salt products, 18.35% from veterinary raw materials, 7.46% from fluorine-containing chemicals, and 4.28% from other products [1] Group 2 - From the perspective of fund holdings, one fund under Huaxia Fund has a significant position in Dayang Biological, specifically the Huaxia Steady Growth One-Year Holding Mixed A fund, which held 2,400 shares, accounting for 0.14% of the fund's net value [2] - The Huaxia Steady Growth One-Year Holding Mixed A fund was established on August 11, 2023, with a latest scale of 29.2614 million CNY, and has achieved a year-to-date return of 1.93% [2] - The fund manager, Song Yang, has been in the position for 8 years and 304 days, with the fund's total asset scale at 9.393 billion CNY, achieving a best return of 76.17% and a worst return of -13.01% during his tenure [2]

Core Viewpoint - On September 12, 2025, the company announced the election of Mr. Guan Weijun as the employee representative director of the sixth board of directors during the employee representative assembly [1] Group 1 - The employee representative assembly was held on September 12, 2025 [1] - The assembly involved democratic discussion and voting [1] - Mr. Guan Weijun was elected as the employee representative director [1]

Group 1 - The company, Dayang Bio (SZ 003017), held its sixth board meeting on September 12, 2025, to review various proposals, including the confirmation of the audit committee members and the convener [1] - For the first half of 2025, the company's revenue composition was 95.72% from the chemical industry and 4.28% from other sources [1] - As of the report date, Dayang Bio's market capitalization was 2.8 billion yuan [1]